BusinessArea
We will keep the competitiveness of the global market based on advanced technology.
Home
Business Areas
Cure Bio
ARS platform technology
BIOCON
-
KRS
Immunomodulatory
antifibrotic drug
(pulmonary
hypertension) -
GRS
Anti-carcinogenic
new mechanism drug
(renal cell carcinoma/ liver cancer/
lung cancer/ ovarian cancer) -
KRAS targeting ARS
Target mechanism
anticancer drug
(colon cancer) -
MRS
Anticancer drug
(pancreatic cancer)
BIOCON
(Medical Bioconvergence Research Group)
-
Established
2010 (Global Frontier Project Group)
-
Research Objective
Target factory (Establishment of a new drug discovery system focusing on ARS)
-
Major theses
Approx. 200 theses and 200 patents (Identification of the correlation between ARS and various diseases and treatment mechanisms)
Cure Bio
and the peptide made on such base induces the death of cancer cell by the same method of human immune system. Neopep GT confirmed better cancer cell inhibition than traditional anticancer medicine(Sunitinib).
Neopep GT(kidney cancer)
Neopep GT discovers the parts combining with CDH6 receptor by analyzing GRS structure secreted to macrophage,and the peptide made on such base induces the death of cancer cell by the same method of human immune system. Neopep GT confirmed better cancer cell inhibition than traditional anticancer medicine(Sunitinib).
Action mechanism
In-vivo test result
Cure Bio
Neopep A1H(Stem cell activator hair loss treatment)
Neopep A1H activates the β-catenin signal system on hair follicle stem cell and dermal papilla cell, which plays a key role for hair growth and maintenance, to allow hair growing. Neopep A1H cannot penetrate into the skin as it is a peptide and activates only hair stem cell through along the pores (secure relative stability).
Action mechanism
In-vivo test result
Clinical Plan
Quotation and contact
If you have any inquiries and need to get a quotation from us, please send an with some information below
